EUVIMEDEUVIMED entdecken
Crossref

MRI-derived real PSA density for risk stratification of PI-RADS 3 lesions: A rule-in approach for clinically significant prostate cancer

Özkan Özdemir

Magnetic Resonance Imaging · 2026-11 · 133 · 110732

DOI: 10.1016/j.mri.2026.110732 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Magnetic Resonance Imaging, 2026-11. Verfasst von Özkan Özdemir. Beteiligte Einrichtung: Department of Radiology, Ankara Bilkent City Hospital, Üniversiteler Mahallesi, Bilkent Bulvarı No:1, 06800 Çankaya, Ankara, Turkey. Electronic addre…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostate-Specific Antigen, Magnetic Resonance Imaging. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Management of PI-RADS 3 lesions remains challenging due to their variable probability of clinically significant prostate cancer (csPCa). Conventional prostate-specific antigen density (PSAD) assumes homogeneous PSA production across the prostate, which may not reflect underlying tissue heterogeneity. This retrospective single-center study included 116 patients with PI-RADS 3 lesions who underwent multiparametric MRI followed by systematic biopsy. Real PSA density (rPSAD) was calculated by normalizing serum PSA to an MRI-derived PSA-producing volume incorporating glandular proxy volume and inflammation-adjusted peripheral zone contribution. csPCa was detected in 20 patients (17%). Among evaluated PSA-based metrics, rPSAD demonstrated the highest discrimination (apparent AUC 0.848; bootstrap-corrected AUC 0.846; 95% CI 0.767-0.924). After Holm-Bonferroni correction, rPSAD significantly outperformed PSA and PZ-PSAD (both adjusted p < 0.001). In a pre-specified multivariable model adjusted for age and prostate volume, rPSAD remained independently associated with csPCa (adjusted OR 2.03 per 0.1 increase; 95% CI 1.48-2.78; p < 0.001). A pre-specified sequential strategy stratified patients into low-risk (PSAD

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstate-Specific AntigenMagnetic Resonance ImagingHumansMaleRetrospective StudiesAgedMiddle AgedRisk AssessmentProstateBiopsyMultiparametric Magnetic Resonance ImagingClinical Relevance

Stichwörter der Autor:innen

Multiparametric MRIPI-RADS 3PSA densityProstate cancerRisk stratification

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Radiology, Ankara Bilkent City Hospital, Üniversiteler Mahallesi, Bilkent Bulvarı No:1, 06800 Çankaya, Ankara, Turkey. Electronic address: mdozkanozdemir@gmail.com.

Zitieren

APA

Özdemir, Ö. (2026). MRI-derived real PSA density for risk stratification of PI-RADS 3 lesions: A rule-in approach for clinically significant prostate cancer. Magnetic Resonance Imaging, 133, 110732. https://doi.org/10.1016/j.mri.2026.110732

Vancouver

Özdemir Ö. MRI-derived real PSA density for risk stratification of PI-RADS 3 lesions: A rule-in approach for clinically significant prostate cancer. Magnetic Resonance Imaging. 2026;133:110732. doi:10.1016/j.mri.2026.110732

BibTeX
@article{zdemir2026,
  author = {Özdemir, Özkan},
  title = {MRI-derived real PSA density for risk stratification of PI-RADS 3 lesions: A rule-in approach for clinically significant prostate cancer},
  journal = {Magnetic Resonance Imaging},
  year = {2026},
  volume = {133},
  pages = {110732},
  doi = {10.1016/j.mri.2026.110732}
}
Kostenlos starten →